Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Above 50-Day Moving Average – Here’s What Happened

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $6.38 and traded as high as $6.60. Karyopharm Therapeutics shares last traded at $6.33, with a volume of 108,045 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on KPTI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a report on Wednesday, October 8th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday, October 9th. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Finally, HC Wainwright raised Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a report on Monday, October 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.20.

Karyopharm Therapeutics Stock Down 1.4%

The firm has a market capitalization of $54.88 million, a PE ratio of -0.43 and a beta of 0.34. The stock has a 50-day moving average price of $6.38 and a 200 day moving average price of $5.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million during the quarter, compared to analyst estimates of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Karyopharm Therapeutics in the first quarter valued at approximately $523,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $56,000. Silverback Asset Management LLC boosted its stake in shares of Karyopharm Therapeutics by 40.0% in the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after acquiring an additional 20,000 shares during the last quarter. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $45,000. Finally, Bank of America Corp DE boosted its stake in shares of Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after acquiring an additional 35,626 shares during the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).